
EOFlow loses appeal against Insulet in EU patent dispute, faces sales ban in 17 countries
EOFlow, the Korean medtech company known for developing Korea’s first and the world’s second wearable insulin pump, has lost its appeal against U.S. rival Insulet in an ongoing injunction case, leading to a sales and distribution ban across 17 European …